アウトブレイク中の流行性耳下腺炎を発症するリスクが高い人に対するムンプスウイルス含有ワクチンの3回目の投与に関するAdvisory Committee on Immunization Practicesの勧告

日本語
English

ホーム IMICライブラリ MMWR抄訳 2018年（Vol.67)アウトブレイク中の流行性耳下腺炎を発症するリスクが･･･

MMWR抄訳

2018/01/12Vol. 67 / No. 1

MMWR67(1):33－38
Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus–Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak

アウトブレイク中の流行性耳下腺炎を発症するリスクが高い人に対するムンプスウイルス含有ワクチンの3回目の投与に関するAdvisory Committee on Immunization Practicesの勧告

2015年後半以降、アメリカでは流行性耳下腺炎のアウトブレイクやアウトブレイク関連の症例数が大幅に増加した。この公衆衛生上の問題に取り組むために、Advisory Committee on Immunization Practices(ACIP)は入手可能なエビデンスのレビューを実施した。取り上げられたトピックには、麻疹-流行性耳下腺炎-風疹(MMR)ワクチンの定期的な2回接種の導入以来の、流行性耳下腺炎の疫学、有効性、防御期間、免疫原性、2回投与のワクチン不全の危険因子、また、 MMRワクチンの3回目の接種の有効性、免疫原性、安全性が含まれた。さらに、 MMRワクチンの3回目の接種の認識された有益性および有害性に起因するステークホルダーの価値観、受容性、実効性についても調査した。流行性耳下腺炎の予防のためのMMRワクチンの3回目の接種の使用に関する3件の疫学的研究は、2回のMMRワクチン接種率が高い集団(学校、大学)でアウトブレイク中に実施された。すべての試験で、アウトブレイク中に3回目の接種をした人はアウトブレイク前に2回の接種を受けた人に比べ、発病率が低下し、1件の研究では有意な差があった(1000人-年あたり6.7 vs. 14.5)。3回目の接種の2回接種に対する増分有効性は61％～88％であった。ステークホルダーの調査の結果、専門家は、学生および両親は流行性耳下腺炎やその合併症の予防にも高い価値を置き、MMRワクチンの3回目の接種の安全性に関する懸念はないと結論した。2017年10月の会議中に、ACIPはアウトブレイクのために流行性耳下腺炎の発症のリスクが高いグループまたは集団に属しているとして、公共の保健機関により同定され、既に2回のワクチン接種をした人に対して、ムンプスウイルス含有ワクチンの3回目投与を推奨した。この勧告の目的は、流行性耳下腺炎の疾患および流行性耳下腺炎に関連する合併症に対して、アウトブレイクの状況にある人々の保護を改善することある。この勧告は、流行性耳下腺炎予防接種のための既存のACIP勧告を補足するものである。

References

Clemmons NS, Redd S, Fiebelkorn AP, et al. Mumps: July 2010–2015, 2016, and beyond. Presentation at the 47th National Immunization Conference; September 14, 2016; Atlanta, GA.
Clemmons NS, Lee AD, Lopez A, et al. Reported mumps cases (Jan 2011–Jun 2017) and outbreaks (Jan 2016–Jun 2017) in the United States. Presentation at ID Week 2017; October 4–8, 2017; San Diego, CA.
McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(No. RR-04).
CDC. Mumps vaccine. MMWR Morb Mortal Wkly Rep 1977;26:393–4.
CDC. Measles prevention. MMWR Suppl 1989;38:1–18.
Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. N Engl J Med 2008;358:1580–9. ＜https://doi.org/10.1056/NEJMoa0706589＞
CDC. Notice to readers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps. MMWR Morb Mortal Wkly Rep 2006;55:629–30.
Marin M. Update on mumps epidemiology, United States. Presentation at the Advisory Committee on Immunization Practices meeting; October 25–26, 2017; Atlanta, GA. ＜https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-10/mumps-02-marin-508.pdf＞
Clemmons N, Hickman C, Lee A, Marin M, Patel M. Mumps [chapter 9]. In: CDC. Manual for the surveillance of vaccine-preventable diseases. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. ＜https://www.cdc.gov/vaccines/pubs/surv-manual/chpt09-mumps.pdf＞
Sane J, Gouma S, Koopmans M, et al. Epidemic of mumps among vaccinated persons, the Netherlands, 2009–2012. Emerg Infect Dis 2014;20:643–8. ＜https://doi.org/10.3201/eid2004.131681＞
Zamir CS, Schroeder H, Shoob H, Abramson N, Zentner G. Characteristics of a large mumps outbreak: clinical severity, complications and association with vaccination status of mumps outbreak cases. Hum Vaccin Immunother 2015;11:1413–7. ＜https://doi.org/10.1080/21645515.2015.1021522＞
Cardemil CV, Dahl RM, James L, et al. Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med 2017;377:947–56. ＜https://doi.org/10.1056/NEJMoa1703309＞
Greenland K, Whelan J, Fanoy E, et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands, 2010. Vaccine 2012;30:4676–80. ＜https://doi.org/10.1016/j.vaccine.2012.04.083＞
Takla A, Böhmer MM, Klinc C, et al. Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Hum Vaccin Immunother 2014;10:140–5. ＜https://doi.org/10.4161/hv.26642＞
Vygen S, Fischer A, Meurice L, et al. Waning immunity against mumps in vaccinated young adults, France 2013. Euro Surveill 2016;21:30156. ＜https://doi.org/10.2807/1560-7917.ES.2016.21.10.30156＞
Livingston KA, Rosen JB, Zucker JR, Zimmerman CM. Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. Vaccine 2014;32:369–74. ＜https://doi.org/10.1016/j.vaccine.2013.11.021＞
Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. Emerg Infect Dis 2007;13:12–7. ＜https://doi.org/10.3201/eid1301.060649＞
Cortese MM, Jordan HT, Curns AT, et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis 2008;46:1172–80. ＜https://doi.org/10.1086/529141＞
Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis 2012;206:1542–8. ＜https://doi.org/10.1093/infdis/jis568＞
Latner DR, McGrew M, Williams N, et al. Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis. Clin Vaccine Immunol 2011;18:35–42. ＜https://doi.org/10.1128/CVI.00284-10＞
Rubin SA, Qi L, Audet SA, et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis 2008;198:508–15. ＜https://doi.org/10.1086/590115＞
Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008;197:950–6. ＜https://doi.org/10.1086/528993＞
LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009;199:552–60. ＜https://doi.org/10.1086/596207＞
Rubin SA, Link MA, Sauder CJ, et al. Recent mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol 2012;86:615–20. ＜https://doi.org/10.1128/JVI.06125-11＞
Nelson GE, Aguon A, Valencia E, et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control—Guam 2009 to 2010. Pediatr Infect Dis J 2013;32:374–80. ＜https://doi.org/10.1097/INF.0b013e318279f593＞
Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics 2012;130:e1567–74. ＜https://doi.org/10.1542/peds.2012-0177＞
Fiebelkorn AP, Coleman LA, Belongia EA, et al. Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. Open Forum Infect Dis 2014;1:ofu094.
Latner DR, Fiebelkorn AP, McGrew M, et al. Mumps virus nucleoprotein and hemagglutinin-specific antibody response following a third dose of measles, mumps, rubella (MMR) vaccine. Open Forum Infect Dis 2017;4:ofx263.
Aasheim ET, Inns T, Trindall A, et al. Outbreak of mumps in a school setting, United Kingdom, 2013. Hum Vaccin Immunother 2014;10:2446–9. ＜https://doi.org/10.4161/hv.29484＞
Abedi GR, Mutuc JD, Lawler J, et al. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak. Vaccine 2012;30:7052–8. ＜https://doi.org/10.1016/j.vaccine.2012.09.053＞
Albertson JP, Clegg WJ, Reid HD, et al. Mumps outbreak at a university and recommendation for a third dose of measles-mumps-rubella vaccine—Illinois, 2015–2016. MMWR Morb Mortal Wkly Rep 2016;65:731–4. ＜https://doi.org/10.15585/mmwr.mm6529a2＞
Marlow M. Grading of recommendations assessment, development and evaluation (GRADE): third dose of MMR vaccine. Presentation at the Advisory Committee on Immunization Practices meeting, October 25–26, 2017; Atlanta, GA. ＜https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-10/mumps-03-marlow-508.pdf＞
Marin M. Considerations for the use of the 3rd dose of MMR vaccine for persons at increased risk because of a mumps outbreak and proposed recommendations. Presentation at the Advisory Committee on Immunization Practices meeting, October 25–26, 2017; Atlanta, GA. ＜https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-10/mumps-03-marlow-508.pdf＞
Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(RR-3).